Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 2, 2015, Pages 513-521

  Song, Xiang ^a,b   Qian, Xiaoqian ^a,b   Shen, Ming ^b   Jiang, Rong ^b   Wagner, Mary B ^b   Ding, Guoliang ^b   Chen, Guangping ^b   Shen, Baozhong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Cardiac fibrosis; Collagen; Heart failure; Protein kinase

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; COLLAGEN TYPE 1; GALECTIN 3; PHORBOL DIBUTYRATE; PROTEIN KINASE C ALPHA; FIBRONECTIN; PROTEIN KINASE C;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE; LUNG ARTERY BANDING; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; ANIMAL; CELL LINE; DRUG EFFECTS; ECHOGRAPHY; ENZYME ACTIVATION; FIBROSIS; HEART MUSCLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY ARTERY; SPRAGUE DAWLEY RAT;

RATTUS;

ANGIOTENSIN II; ANIMALS; CELL LINE; COLLAGEN TYPE I; ENZYME ACTIVATION; FIBRONECTINS; FIBROSIS; GALECTIN 3; HEART FAILURE; MALE; MICE; MYOCARDIUM; PROTEIN KINASE C; PULMONARY ARTERY; RATS, SPRAGUE-DAWLEY;

EID: 84919941043     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.12.001     Document Type: Article

References (40)

1. Liu Q., Molkentin J.D. Protein kinase Calpha as a heart failure therapeutic target. J. Mol. Cell. Cardiol. 2011, 51:474-478.
2. Morrow D.A., O'Donoghue M.L. Galectin-3 in cardiovascular disease: a possible window into early myocardial fibrosis. J. Am. Coll. Cardiol. 2012, 60:1257-1258.
3. Bogaard H.J., Abe K., Vonk Noordegraaf A., Voelkel N.F. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009, 135:794-804.
4. Karamanlidis G., Bautista-Hernandez V., Fynn-Thompson F., Del Nido P., Tian R. Impaired mitochondrial biogenesis precedes heart failure in right ventricular hypertrophy in congenital heart disease. Circ. Heart Fail. 2011, 4:707-713.
5. Voelkel N.F., Gomez-Arroyo J., Abbate A., Bogaard H.J., Nicolls M.R. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur. Respir. J. 2012, 40:1555-1565.
6. Braz J.C., Gregory K., Pathak A., Zhao W., Sahin B., Klevitsky R., Kimball T.F., Lorenz J.N., Nairn A.C., Liggett S.B., Bodi I., Wang S., Schwartz A., Lakatta E.G., DePaoli-Roach A.A., Robbins J., Hewett T.E., Bibb J.A., Westfall M.V., Kranias E.G., Molkentin J.D. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat. Med. 2004, 10:248-254.
7. Bayer A.L., Heidkamp M.C., Patel N., Porter M., Engman S., Samarel A.M. Alterations in protein kinase C isoenzyme expression and autophosphorylation during the progression of pressure overload-induced left ventricular hypertrophy. Mol. Cell. Biochem. 2003, 242:145-152.
8. Bowling N., Walsh R.A., Song G., Estridge T., Sandusky G.E., Fouts R.L., Mintze K., Pickard T., Roden R., Bristow M.R., Sabbah H.N., Mizrahi J.L., Gromo G., King G.L., Vlahos C.J. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 1999, 99:384-391.
9. Wang J., Liu X., Sentex E., Takeda N., Dhalla N.S. Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2003, 284:H2277-H2287.
10. Steinberg S.F. Cardiac actions of protein kinase C isoforms. Physiology (Bethesda) 2012, 27:130-139.
11. Belin R.J., Sumandea M.P., Allen E.J., Schoenfelt K., Wang H., Solaro R.J., de Tombe P.P. Augmented protein kinase C-alpha-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure. Circ. Res. 2007, 101:195-204.
12. Braz J.C., Bueno O.F., De Windt L.J., Molkentin J.D. PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2). J. Cell Biol. 2002, 156:905-919.
13. Schroen B., Heymans S., Sharma U., Blankesteijn W.M., Pokharel S., Cleutjens J.P., Porter J.G., Evelo C.T., Duisters R., van Leeuwen R.E., Janssen B.J., Debets J.J., Smits J.F., Daemen M.J., Crijns H.J., Bornstein P., Pinto Y.M. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ. Res. 2004, 95:515-522.
14. Belmonte S.L., Blaxall B.C. PKC-ing is believing: targeting protein kinase C in heart failure. Circ. Res. 2011, 109:1320-1322.
15. Liu Q., Chen X., Macdonnell S.M., Kranias E.G., Lorenz J.N., Leitges M., Houser S.R., Molkentin J.D. Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ. Res. 2009, 105:194-200.
16. Boyle A.J., Kelly D.J., Zhang Y., Cox A.J., Gow R.M., Way K., Itescu S., Krum H., Gilbert R.E. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J. Mol. Cell. Cardiol. 2005, 39:213-221.
17. Connelly K.A., Kelly D.J., Zhang Y., Prior D.L., Advani A., Cox A.J., Thai K., Krum H., Gilbert R.E. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ. Heart Fail. 2009, 2:129-137.
18. Ladage D., Tilemann L., Ishikawa K., Correll R.N., Kawase Y., Houser S.R., Molkentin J.D., Hajjar R.J. Inhibition of PKCalpha/beta with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury. Circ. Res. 2011, 109:1396-1400.
19. Sharma U.C., Pokharel S., van Brakel T.J., van Berlo J.H., Cleutjens J.P., Schroen B., Andre S., Crijns H.J., Gabius H.J., Maessen J., Pinto Y.M. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
20. Liu Y.H., D'Ambrosio M., Liao T.D., Peng H., Rhaleb N.E., Sharma U., Andre S., Gabius H.J., Carretero O.A. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H404-H412.
21. Yu L., Ruifrok W.P., Meissner M., Bos E.M., van Goor H., Sanjabi B., van der Harst P., Pitt B., Goldstein I.J., Koerts J.A., van Veldhuisen D.J., Bank R.A., van Gilst W.H., Sillje H.H., de Boer R.A. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ. Heart Fail. 2013, 6:107-117.
22. Ho J.E., Liu C., Lyass A., Courchesne P., Pencina M.J., Vasan R.S., Larson M.G., Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 2012, 60:1249-1256.
23. de Couto G., Ouzounian M., Liu P.P. Early detection of myocardial dysfunction and heart failure. Nat. Rev. Cardiol. 2010, 7:334-344.
24. Li X., Yang B., Chen M., Klein J.D., Sands J.M., Chen G. Activation of protein kinase C-alpha and Src kinase increases urea transporter A1 alpha-2, 6 sialylation. J. Am. Soc. Nephrol. 2014, [in Press].
25. Schou U.K., Peters C.D., Kim S.W., Frokiaer J., Nielsen S. Characterization of a rat model of right-sided heart failure induced by pulmonary trunk banding. J. Exp. Anim. Sci. 2007, 43:18.
26. Slama M., Ahn J., Peltier M., Maizel J., Chemla D., Varagic J., Susic D., Tribouilloy C., Frohlich E.D. Validation of echocardiographic and Doppler indexes of left ventricular relaxation in adult hypertensive and normotensive rats. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H1131-H1136.
27. Mori J., Zhang L., Oudit G.Y., Lopaschuk G.D. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure. J. Mol. Cell. Cardiol. 2013, 63:98-106.
28. Snijder P.M., Frenay A.S., de Boer R.A., Pasch A., Hillebrands J., Leuvenink H.G., van Goor H. Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates Angiotensin II-induced hypertensive heart disease in rats. Br. J. Pharmacol. 2014, [in Press].
29. Goldberg M., Steinberg S.F. Tissue-specific developmental regulation of protein kinase C isoforms. Biochem. Pharmacol. 1996, 51:1089-1093.
30. Simonis G., Briem S.K., Schoen S.P., Bock M., Marquetant R., Strasser R.H. Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy. Mol. Cell. Biochem. 2007, 305:103-111.
31. Ueland T., Aukrust P., Broch K., Aakhus S., Skardal R., Muntendam P., Gullestad L. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int. J. Cardiol. 2011, 150:361-364.
32. de Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur. J. Heart Fail. 2009, 11:811-817.
33. Ahmad T., Felker G.M. Galectin-3 in heart failure: more answers or more questions?. J. Am. Heart Assoc. 2012, 1:e004374.
34. Azibani F., Fazal L., Chatziantoniou C., Samuel J.L., Delcayre C. Aldosterone mediates cardiac fibrosis in the setting of hypertension. Curr. Hypertens. Rev. 2013, 15:395-400.
35. Reifenberg K., Lehr H.A., Torzewski M., Steige G., Wiese E., Kupper I., Becker C., Ott S., Nusser P., Yamamura K., Rechtsteiner G., Warger T., Pautz A., Kleinert H., Schmidt A., Pieske B., Wenzel P., Munzel T., Lohler J. Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am. J. Pathol. 2007, 171:463-472.
36. Thandavarayan R.A., Watanabe K., Ma M., Veeraveedu P.T., Gurusamy N., Palaniyandi S.S., Zhang S., Muslin A.J., Kodama M., Aizawa Y. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem. Pharmacol. 2008, 75:1797-1806.
37. Sharma U., Rhaleb N.E., Pokharel S., Harding P., Rasoul S., Peng H., Carretero O.A. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H1226-H1232.
38. Henderson N.C., Mackinnon A.C., Farnworth S.L., Kipari T., Haslett C., Iredale J.P., Liu F.T., Hughes J., Sethi T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 2008, 172:288-298.
39. Henderson N.C., Mackinnon A.C., Farnworth S.L., Poirier F., Russo F.P., Iredale J.P., Haslett C., Simpson K.J., Sethi T. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5060-5065.
40. Kasper M., Hughes R.C. Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. J. Pathol. 1996, 179:309-316.